Why the study?
Anthracycline treatment in diffuse large B-cell lymphoma can be difficult or contraindicated due to coexisting cardiovascular diseases, making liposomal formulations a potential alternative.
Does non-pegylated liposomal doxorubicin-based immunochemotherapy (R-COMP) provide safe and effective treatment in an elderly patient with DLBCL and high cardiovascular risk?
Does non-pegylated liposomal doxorubicin-based immunochemotherapy (R-COMP) provide safe and effective treatment in an elderly patient with DLBCL and high cardiovascular risk?
Non-pegylated liposomal doxorubicin (R-COMP) may be a safe and effective alternative to conventional anthracyclines in elderly lymphoma patients with high cardiovascular risk.
Liposomal anthracyclines may be feasible in DLBCL with cardiovascular comorbidities; hypothesis-generating and requires prospective confirmation.
The use of anthracyclines in the treatment of patients with diffuse large B cell lymphoma is crucial, however may be sometimes difficult or even contraindicated due to coexisting cardiovascular diseases. An alternative to conventional anthracyclines seems to be liposomal forms that have been registered in the first line of treatment for women with metastatic breast cancer. Data on their use in patients with non-Hodgkin’s lymphomas indicate high efficacy and acceptable toxicity. We present case report of treatment with immunochemotherapy using non-pegylated liposomal doxorubicin in elderly woman with diffuse large B-cell lymphoma coexisting with ischemic heart disease, hypertension, type 2 diabetes. In addition, we present review of literature and the aspects of the use of drugs off-label.
No takes yet. Share an insight, caveat, or question.
Joks et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: